The US FDA has approved non-invasive, continuous SpHb for patients weighing 3kg, and is not currently indicated for patients weighing less than 3kg in the US.
US-based non-invasive patient monitoring technologies manufacturer Masimo has received the CE mark for its SpHb, a non-invasive and continuous haemoglobin monitor, for neonatal and infant patients below 3kg.
Masimo said that its SpHb for neonates and infants is equipped with rainbow sensors, to measure multiple additional non-invasive parameters along with SpHb, including oxygen saturation (SpO2) and methaemoglobin (SpMet).
Neonates and infants have less blood than older patients, due to their smaller size, and are less capable of generating new red blood cells for nearly first eight months of life due to the lack of bone marrow density.
CE mark approval of the SpHb ensures its benefits are available for patients of all ages in CE countries.
SpHb offer continuous, non-invasive measurement
According to Masimo, the invasive methodologies currently in use for measuring haemoglobin would provide only discontinuous delayed results, while its SpHb provides continuous, non-invasive measurement.
In addition, SpHb tracks the stability, or instability, of a patient’s haemoglobin trend, providing a view into changes, or lack of changes, in haemoglobin between invasive blood samples to enable clinicians closely monitor neonatal haemoglobin status in real time.
Masimo founder and CEO Joe Kiani said: “We are thrilled to be able to bring the power of noninvasive haemoglobin monitoring with SpHb to the youngest, most fragile patients of all. We have long been dedicated to helping improve the lives of neonatal and infant patients, and this latest clearance significantly furthers that mission.
“SpHb is already used to monitor adult patients in more than 75 countries. We look forward to witnessing the impact that SpHb will now be able to have on neonatal and infant patients.”
Continuous blood monitoring in adult patients using SpHb has been found to improve outcomes, including reduced percentage of patients receiving transfusions, units of red blood cells transfused per patient, time taken for transfusion, costs, and mortality rate 30 days after surgery.
Besides, the rainbow sensors are capable of monitoring SpO2 using Masimo SET Measure-through Motion and Low Perfusion technology which demonstrated its ability in various studies to outperform other pulse oximetry technologies.